Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; and Sara Nunnery, MD, MSCI, review pivotal clinical trials investigating novel endocrine therapies and targeted combination regimens for hormone receptor-positive, HER2-negative metastatic breast cancer, and discuss strategies for selecting the optimal treatment approach for individual patients.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate recent clinical trial data supporting novel therapies and combinations for HR+/HER2– metastatic breast cancer (MBC)
• ·Apply practical strategies for tailoring first-line and subsequent therapy choices based on patient, disease, and biomarker characteristics in HR+/HER2– MBC

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc; Genentech, Inc; Lilly; and Stemline Therapeutics.

Chair:

Kevin Kalinsky, MD, MS

Professor, Department of Hematology and Medical
Oncology
Winship Cancer Institute of Emory University
Atlanta, GA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Bicycle Therapeutics, Biotheranostics, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Gilead, Jazz Pharmaceuticals, Menarini Silicon Biosystems, Merck, Mersana, Myovant Sciences, Novartis, Pfizer, ProteinQure, Puma Biotechnology, RayzeBio, Regor, Relay Therapeutics, Seattle Genetics

Faculty:

Adam Brufsky, MD, PhD

Professor of Medicine
Co-Director, Cancer Therapeutics Program
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Agendia, AstraZeneca, Bria-Cell, Celcuity, Daiichi Sankyo, Genentech/Roche, Gilead, Lilly, Merck, Myriad, Novartis, Pfizer, Puma, Sanofi; Ownership interests in privately held companies: Celcuity

Kelly Elizabeth McCann, MD, PhD

Assistant Clinical Professor
David Geffen School of Medicine
Jonsson Comprehensive Cancer Center
UCLA Hematology and Oncology
Los Angeles, CA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Arvinas, AstraZeneca, BioNTech, Biotheranostics, Biovica, Daiichi Sankyo, Eli Lilly, Halda Therapeutics OpCo, Novartis, Pfizer, Puma Biotech, Sermonix, Stemline, Summit Therapeutics, TerSera; Speakers Bureau: Eli Lilly; Grant/Research Funding: Ambrx, AstraZeneca, BriaCell, Duality Biologics, Eli Lilly, G1 Therapeutics, Gilead, H3 Biomedicine, Immunomedics, MacroGenics, Marengo Therapeutics, Merck, Novartis, Olema, Pfizer, Puma Biotech, Roche/Genentech, Sanofi, Stemline, Zymeworks

Sara Nunnery, MD, MSCI

Director of Breast Cancer Research
Tennessee Oncology
Nashville, TN

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Arvinas, Daiichi Sankyo, Gilead, Menarini Stemline, Merck, Novartis, Pfizer; Grant/Research Funding: AstraZeneca, BioNTech, DualityBio, Genentech, Olema, Menarini Stemline, Merck, Puma Biotechnology, Relay Therapeutics

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by an AI tool.

To learn more about this topic, including information on current treatment options for HR+/HER2- MBC across the continuum from endocrine-sensitive to endocrine-resistant disease, go https://www.gotoper.com/mbcc26her2-activity.

Release Date

April 23, 2026

Expiration Date

April 23, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.